The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
about
What can imaging tell us about cognitive impairment and dementia?Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes.Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [(18)F]FP-CIT PET/CTThe utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes.Imaging approaches for dementia.Neuroimaging: current role in detecting pre-motor Parkinson's disease.Correlative (99m)tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease.Recognizing uncommon presentations of psychogenic (functional) movement disorders.CT-based attenuation correction in I-123-ioflupane SPECTHow useful is [123I]beta-CIT SPECT in clinical practice?Patient Survey on Satisfaction and Impact of 123I-Ioflupane Dopamine Transporter Imaging.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.The Role of the Serotonergic System in REM Sleep Behavior Disorder.Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's diseaseInvestigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.Striatal dopaminergic functioning in patients with sporadic and hereditary spastic paraplegias with parkinsonism.Single photon-emission computed tomography imaging in early Parkinson's disease.Recognition and management of Parkinson's disease during the premotor (prodromal) phase.SPECT imaging evaluation in movement disorders: far beyond visual assessment.The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration.Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study.Radius dependence of FP-CIT quantification: a Monte Carlo-based simulation study.Establishing On-Site Reference Values for (123)I-FP-CIT SPECT (DaTSCAN®) Using a Cohort of Individuals with Non-Degenerative Conditions.Molecular SPECT Imaging: An Overview.Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT.The role of I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies.Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease?[123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease.Correlation between clinical symptoms and striatal DAT uptake in patients with DLB.Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes.Weighted registration of 123I-FP-CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake.Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB.Robust, fully automatic delineation of the head contour by stereotactical normalization for attenuation correction according to Chang in dopamine transporter scintigraphy.Automatic assistance to Parkinson's disease diagnosis in DaTSCAN SPECT imaging.Changes in clinical management and diagnosis following DaTscan SPECT imaging in patients with clinically uncertain parkinsonian syndromes: a 12-week follow-up study.Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls.Optimization of iterative reconstruction parameters with 3-dimensional resolution recovery, scatter and attenuation correction in ¹²³I-FP-CIT SPECT.
P2860
Q26749292-67D57921-3FCE-494B-B027-41646F46D3C3Q30480599-EFF9857D-5EF4-429E-90AA-843AE973AB9EQ33639396-A4FB2222-4182-4B92-ADA5-5BB375FCEBBAQ33693399-219A2B26-7005-4675-89EF-766785C37EE2Q34089121-B03E6B3E-6F9D-4F17-ACA9-E4F336FB6188Q34234625-699D069E-2EFF-46AF-8881-368FD899CDBDQ34675764-260297D2-907E-46ED-A53A-B217D7AC29DCQ35002512-D1CA255B-A437-451A-A4C2-DDD475FFBDB8Q35287222-BFD06ACE-F264-426C-A3A3-5F8110182034Q35489842-993C70A5-37CA-4BB7-893D-C4F3A344BFF1Q35726821-DCC47077-BFDF-4062-9ADE-779AC86AE3F2Q35910290-43BE57BE-EC2E-48AA-B133-BDA8CCD8E2FDQ35936402-B4EB698A-60CB-4733-9AD1-92BC9B533C67Q36226812-E76B172A-592F-4DCD-A748-C7C3AD02A3D2Q36373719-2359E684-A5E3-4F39-B077-0C8D04DBCE04Q37106123-E2B1E7C5-9018-4887-98FC-9C4283C0A1C7Q37329628-3F1E7E70-2F90-4621-AA2A-369C6482AF48Q37352055-22158219-F5F7-419A-90EF-0CD494F11DEFQ37507968-4DA20AD4-9242-46DE-89C4-96E00397B88AQ37815026-E41CE58F-662E-412D-A302-B3B7C2CCCD29Q37910636-92D9B37B-66B1-40C5-9B37-7391EC74AFD7Q38642358-E8C4117D-E941-43EB-AEC0-BBA7499E7D2DQ40151900-5721AF5F-3DAD-4767-B865-D3A75921B0E4Q41409967-9FB97B18-82DA-4B5E-854E-4C9D5538F0C4Q41882052-6334F6BA-2F28-40FA-AAA7-939F28896D09Q42470263-507A1AB2-7EC9-4D9C-ADDA-B9FBD2DDCD8AQ43164212-9EB30925-7203-4558-9534-59A575DFCD25Q43971537-1776499A-60EF-4710-8756-A35FBDB9299DQ45729007-BB97C849-DEC4-4423-8439-0CCE6BC88D2FQ46002352-ED9A03AB-2BE0-434F-A43A-5C4634B518A2Q46775404-5AE652FC-63A5-49C6-B4C1-99B93C7C3216Q47748535-E25F2720-F0B8-4A42-8973-8A857D6F0B8CQ47911714-8321F743-9298-4069-8AC1-BBF2F85C785DQ48095805-C083F8F5-9C9C-487B-BF80-053E2B8A5F43Q48111729-03B24BC3-2180-49B2-AAF7-F904BB8D3AE8Q48309245-A099E8DC-5B76-4B58-B6F4-E4F2C08F61F1Q48348452-2C6F875E-23F3-44AD-A67B-393C33682AEBQ48444801-57F2CE28-D610-4010-856F-944B0703C96CQ48693663-A0C52D5B-1D62-4034-9A37-D708C685579BQ48799965-FAE86A52-B4CE-4AFB-AF23-FC06E6FCE9C1
P2860
The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The clinical benefit of imagin ...... h other forms of parkinsonism.
@en
The clinical benefit of imagin ...... h other forms of parkinsonism.
@nl
type
label
The clinical benefit of imagin ...... h other forms of parkinsonism.
@en
The clinical benefit of imagin ...... h other forms of parkinsonism.
@nl
prefLabel
The clinical benefit of imagin ...... h other forms of parkinsonism.
@en
The clinical benefit of imagin ...... h other forms of parkinsonism.
@nl
P2093
P921
P356
P1476
The clinical benefit of imagin ...... h other forms of parkinsonism.
@en
P2093
Horstink MW
Speelman JD
Wolters EC
P2888
P304
P356
10.1007/S002590000460
P577
2001-03-01T00:00:00Z